Fortress Biotech, Inc. (FBIO) Stock Price & Analysis
Fortress Biotech, Inc. (FBIO) rose 2.81% to USD 2.93 as of June 10, 2026 at 07:32 UTC, according to Nexqual real-time market data.
FBIO last closed at USD 2.85; the session ranged USD 2.82–2.99 on volume of 404,925 shares. Market capitalization is $97.33M, with a 52-week range of USD 1.7–4.53 (NCM). Source: Nexqual, June 10, 2026 at 07:32 UTC.
Key Statistics (as of June 10, 2026 at 07:32 UTC)
| Price | USD 2.93 |
|---|---|
| Change | ▲ 2.81% (up) |
| Previous Close | USD 2.85 |
| Open | USD 2.9 |
| Day Range | USD 2.82 – 2.99 |
| 52-Week Range | USD 1.7 – 4.53 |
| Volume | 404,925 shares |
| Market Cap | $97.33M |
| Exchange | NCM |
Technical Analysis (FBIO)
Nexqual's technical model rates FBIO "STRONG BUY" based on 5 bullish and 0 bearish signals across 123 daily candles, as of June 10, 2026 at 07:32 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 62.71 (neutral) |
| vs SMA50 | Above (USD 2.48) |
| MACD | 0.08 (positive) |
Analyst Ratings (FBIO)
Wall Street analysts rate FBIO "None" based on 2 analysts, with a mean price target of USD 11 (range USD 5–17), per Nexqual as of June 10, 2026 at 07:32 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 11 |
| High Target | USD 17 |
| Low Target | USD 5 |
| Buy / Hold / Sell | 2 / 0 / 0 |
Earnings (FBIO)
| Revenue Estimate | $18.30M |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 2.82 vs est -0.22 ▲ beat |
| 2025-12-31 | USD -0.21 vs est 0.11 ▼ miss |
| 2025-09-30 | USD 0.11 vs est -0.63 ▲ beat |
| 2025-06-30 | USD -0.51 vs est -0.31 ▼ miss |
Source: Nexqual, June 10, 2026 at 07:32 UTC.
Financials & Fundamentals (FBIO)
| Total Revenue | $63.26M |
|---|---|
| Revenue Growth (YoY) | +6.30% |
| Gross Margin | +48.11% |
| Operating Margin | -29.78% |
| Profit Margin | +10.77% |
| ROE | -108.74% |
| Debt / Equity | 108.09 |
| Current Ratio | 2.49 |
| Total Cash | $79.38M |
| Total Debt | $67.22M |
| Free Cash Flow | $-47.29M |
Source: Nexqual, June 10, 2026 at 07:32 UTC.
Financial Health Score (FBIO)
Nexqual rates Fortress Biotech, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 07:32 UTC.
| Growth | Solid — Revenue +10% YoY (annual) |
|---|---|
| Profitability | Mixed — Gross margin 48%, operating -30% |
| Balance Sheet | Mixed — $79M cash vs $67M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$47M, burning cash |
| Efficiency | Critical — ROE -109%, ROA -26.6% |
Ownership (FBIO)
| Insider Ownership | +22.79% |
|---|---|
| Institutional Ownership | +18.16% |
| Shares Outstanding | 33.22M |
| Float | 22.38M |
| Short % of Float | +18.13% |
Source: Nexqual, June 10, 2026 at 07:32 UTC.
Leadership (FBIO)
Fortress Biotech, Inc. is led by Lindsay Allan Rosenwald (age 70), Executive Chairman, President & CEO, per Nexqual as of June 10, 2026 at 07:32 UTC.
| Executive Chairman, President & CEO | Lindsay Allan Rosenwald (age 70) |
|---|---|
| CFO & Head of Corporate Development | David Jin (age 34) |
| Chief Strategy Officer | Xiaoqin Lu (age 50) |
| Executive Vice Chairman of Strategic Development & Director | Michael S. Weiss Esq. (age 59) |
Major Backers & Investors (FBIO)
Notable institutional backers of Fortress Biotech, Inc. include Opaleye Management Inc., Shikiar Asset Management, Inc., GSA Capital Partners LLP, according to Nexqual as of June 10, 2026 at 07:32 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Opaleye Management Inc. | 3.14% |
| Shikiar Asset Management, Inc. | 0.92% |
| GSA Capital Partners LLP | 0.77% |
| Fidelity | 0.72% |
| Susquehanna International Group, LLP | 0.63% |
| Two Sigma Investments, LP | 0.59% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 5.82% |
| Geode Capital | 0.87% |
| BlackRock | 0.78% |
| Northern Trust | 0.69% |
Source: Nexqual, June 10, 2026 at 07:32 UTC.
From Fortress Biotech, Inc.'s Latest SEC 10-K Filing (filed 2026-03-31)
Key Strengths & Strategy (as disclosed to the SEC)
- Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MBIO | Mustang Bio, Inc. | USD 0.74 | ▲ 10.75% |
| ATXI | Avenue Therapeutics, Inc. | USD 0.36 | ▲ 2.27% |
| VSTM | Verastem, Inc. | USD 3.82 | ▲ 2.96% |
| LPCN | Lipocine Inc. | USD 2.05 | ▲ 0% |
| ABEO | Abeona Therapeutics Inc. | USD 5.45 | ▼ 0.18% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 07:32 UTC. This page is informational and not investment advice.